Yong Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yong Luo has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Jingtao Lin
Department of Clinical laboratory, Dalang Hospital of Dongguan City, Dongguan
2 shared publicationsErying Zhang
Kingfocus Biomedical Engineering Co., Ltd Shenzhen China
1 shared publication- Erying Zhang
Research and Development Department, Jinzhun Biological Engineering Co., Ltd. Shenzhen
1 shared publication Jinsong Tang
Department of Clinical Laboratory Dalang Hospital Dongguan China
1 shared publication- Jinsong Tang
Department of Psychiatry, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
1 shared publication Lili Wu
Department of Clinical Laboratory Dalang Hospital Dongguan China
1 shared publication
Latest Publications
- Open Access
- 4 June 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (22) , e26131
Serum IL-6 and procalcitonin are two promising novel biomarkers for evaluating the severity of COVID-19 patients
To evaluate the development of coronavirus disease 2019 (COVID-19), the roles of interleukin 6 (IL-6) and procalcitonin (PCT) were assessed to diagnose severe COVID-19. Between January and February 2020, 100 consecutive patients with confirmed COVID-19 were included and divided into common (n = 56), severe (n = 28), and critical (n = 16) groups. IL-6 and PCT levels were assayed and compared among groups. IL-6 levels were significantly different among groups (common, 23.93±9.64 pg/mL; severe, 69.22 ± 22.98 pg/mL; critical, 160.34 ± 26.15 pg/mL; P < .05), and there was also a significant difference in the levels of PCT among groups (common, 0.23 ± 0.13 ng/mL; severe, 0.38 ± 0.16 ng/mL; critical, 0.73 ± 0.36 ng/mL; P < .05). Further analysis showed that patients in the critical group had the highest levels of IL-6 and PCT, and those in the common group had the lowest levels (all P < .05). IL-6 and PCT are associated with the severity of COVID-19, and thus have potential value in the diagnosis of COVID-19.
- 4 June 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (22) , e26131
Open AccessSerum IL-6 and procalcitonin are two promising novel biomarkers for evaluating the severity of COVID-19 patients
To evaluate the development of coronavirus disease 2019 (COVID-19), the roles of interleukin 6 (IL-6) and procalcitonin (PCT) were assessed to diagnose severe COVID-19. Between January and February 2020, 100 consecutive patients with confirmed COVID-19 were included and divided into common (n = 56), severe (n = 28), and critical (n = 16) groups. IL-6 and PCT levels were assayed and compared among groups. IL-6 levels were significantly different among groups (common, 23.93±9.64 pg/mL; severe, 69.22 ± 22.98 pg/mL; critical, 160.34 ± 26.15 pg/mL; P < .05), and there was also a significant difference in the levels of PCT among groups (common, 0.23 ± 0.13 ng/mL; severe, 0.38 ± 0.16 ng/mL; critical, 0.73 ± 0.36 ng/mL; P < .05). Further analysis showed that patients in the critical group had the highest levels of IL-6 and PCT, and those in the common group had the lowest levels (all P < .05). IL-6 and PCT are associated with the severity of COVID-19, and thus have potential value in the diagnosis of COVID-19.
- Open Access
- 24 March 2021
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 35 (5) , e23752
Development of quantum dot‐based fluorescence lateral flow immunoassay strip for rapid and quantitative detection of serum interleukin‐6
Background: Interleukin‐6 (IL‐6) is an inflammatory factor that increases rapidly in response to infectious diseases including sepsis. The aim of this study is to develop a quantum dot (QD)‐based fluorescence lateral flow immunoassay (LFIA) strip that can rapidly and accurately detect IL‐6 levels.Methods: QD‐based LFIA strips were fabricated by conjugating CdSe/ZnS QDs to the IL‐6 antibody. Performance verification and clinical sample analysis were carried out to evaluate the newly developed strip.Results: QD‐based LFIA strips were successfully fabricated. The test strip's linear range was 10–4000 pg/ml, with a linear correlation coefficient of R2 ≥ .959. The sensitivity of the test strip was 1.995 pg/ml. The recovery rate was 95.72%–102.63%, indicating satisfying accuracy. The coefficient of variation (CV) of the intra‐assay was 2.148%–3.903%, while the inter‐assay was 2.412%–5.293%, verifying the strip's high precision. The cross‐reaction rates with various interleukins (IL‐1α, IL‐1β, IL‐2, IL‐4, and IL‐8) and interferon‐γ (IFN‐γ) were all n = 200, R2 = .9971) for the detection of IL‐6.Conclusions: The QD‐based test strip can rapidly and quantitatively detect IL‐6 levels, thus meeting the requirement of point‐of‐care test (POCT) and showing excellent clinical prospects.
- 24 March 2021
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 35 (5) , e23752
Open AccessDevelopment of quantum dot‐based fluorescence lateral flow immunoassay strip for rapid and quantitative detection of serum interleukin‐6
Background: Interleukin‐6 (IL‐6) is an inflammatory factor that increases rapidly in response to infectious diseases including sepsis. The aim of this study is to develop a quantum dot (QD)‐based fluorescence lateral flow immunoassay (LFIA) strip that can rapidly and accurately detect IL‐6 levels.Methods: QD‐based LFIA strips were fabricated by conjugating CdSe/ZnS QDs to the IL‐6 antibody. Performance verification and clinical sample analysis were carried out to evaluate the newly developed strip.Results: QD‐based LFIA strips were successfully fabricated. The test strip's linear range was 10–4000 pg/ml, with a linear correlation coefficient of R2 ≥ .959. The sensitivity of the test strip was 1.995 pg/ml. The recovery rate was 95.72%–102.63%, indicating satisfying accuracy. The coefficient of variation (CV) of the intra‐assay was 2.148%–3.903%, while the inter‐assay was 2.412%–5.293%, verifying the strip's high precision. The cross‐reaction rates with various interleukins (IL‐1α, IL‐1β, IL‐2, IL‐4, and IL‐8) and interferon‐γ (IFN‐γ) were all n = 200, R2 = .9971) for the detection of IL‐6.Conclusions: The QD‐based test strip can rapidly and quantitatively detect IL‐6 levels, thus meeting the requirement of point‐of‐care test (POCT) and showing excellent clinical prospects.